Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 May 13;137(19):2704-2707.
doi: 10.1182/blood.2020008119.

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R Bolen  1 , Federico Mattiello  2 , Michael Herold  3 , Wolfgang Hiddemann  4 , Sarah Huet  5   6   7 , Wolfram Klapper  8 , Robert Marcus  9 , Farheen Mir  10 , Gilles Salles  5   11 , Oliver Weigert  12   13   14 , Tina Nielsen  2 , Mikkel Z Oestergaard  15 , Jeffrey M Venstrom  16
Affiliations
Comparative Study

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R Bolen et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
High-risk gene signatures are differentially prognostic for PFS in patients treated with bendamustine vs CHOP/CVP. Summary scores were calculated for 5 published gene signatures. High risk for (A) the PRIMA 23-gene signature was defined as patients in the top 25th percentile or (B) the top 75th percentile for the T-effector signature. Patients were split by high-risk status and chemotherapy group, and PFS was plotted as a Kaplan-Meier curve. HR and P value for an interaction term are included. (C) High-risk definitions for gene signatures were evaluated at 3 different quartile cutoffs (25th, 50th, and 75th percentiles). PFS HRs and 95% CIs in the CHOP/CVP cohort (blue) or the bendamustine cohort (red) are plotted. CI, confidence interval; HR, hazard ratio.
Figure 2.
Figure 2.
Evidence of differential prognostic association across all subsets of the 23-gene signature. The association of each gene was tested among patients treated with either CHOP/CVP (blue) or bendamustine (red). PFS HRs and 95% CIs from a multivariate Cox proportional-hazards model are plotted. *Demonstrated significant chemotherapy dependence (interaction, P < .05). CI, confidence interval; HR, hazard ratio.
See this image and copyright information in PMC

References

    1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981-987. - PMC - PubMed
    1. Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540-1547. - PubMed
    1. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. - PubMed
    1. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562. - PubMed
    1. Mir F, Grigg A, Herold M, et al. A novel prognostic model that is superior to FLIPI-1 and FLIPI-2 and integrates clinical and treatment factors to predict progression-free survival and early treatment failure in patients with follicular lymphoma in the GALLIUM trial [abstract]. Blood. 2018;132(suppl 1). Abstract 2872.

Publication types

MeSH terms